CCM disease, which occurs in about one in 100 to 200 people, can present in two forms. One is sporadic, accounting for 80 percent of cases, and is most frequent in older individuals. The remaining 20 percent are familial, inherited cases.
In 2016, the Kahn lab discovered the molecular mechanism in endothelial cells that underlies the formation of CCMs. In the current Nature study, the team discovered that this molecular pathway is activated by TLR4, a receptor for the bacterial molecule lipopolysaccharide (LPS). Activation of TLR4 on brain endothelial cells by LPS vastly accelerated CCM formation. Conversely, if TLR4 was removed from endothelial cells genetically, or if the mice were treated with drugs that block TLR4 function, CCM formation is prevented.
Since TLR4 primarily responds to LPS from
The team next sought evidence that bacterial
«Some of these patients experience severe stroke by the age of two and others have no symptoms over their lifetime," Kahn said. «What makes the disease outcome so variable?»
Working with the team from UNM and UCSF, they discovered that genetic variations that raise the amount of TLR4 that is produced are associated with higher numbers of CCM lesions, suggesting that the key role for
These studies identify an unexpected, direct link between the microbiome and a common cerebrovascular disease. «This suggests that treatments designed to block TLR4 signaling or alter the microbiome may be used to treat this disease," Kahn said.